This is a description of a clinical case of levamisole-induced leukoencephalopathy. A few hours after the single intake of the immunomodulator levamisole (150 mg), the patient developed following cerebral symptoms: febrile fever, dizziness, frequent urination, impaired color vision, divergent strabismus, unsteady gait, severe weakness, increased drowsiness, retardation, delusions. The symptoms progressed towards a full clinical picture for about 2 months. The course of the disease was of a wavy nature: left-sided hemiparesis and the left facial nerve palsy were present at the beginning, with later inversion of symptoms represented by the right-sided hemiparesis and the right facial nerve palsy combined with dysarthria. Magnetic resonance imaging (MRI) revealed multiple foci of demyelination in both hemispheres of the brain that regressed after corticosteroid therapy administration. No abnormalities of the cerebrospinal fluid were detected. No pathology of the fundus was evident. The evoked potentials of the brainstem (auditory and visual) and somatosensory evoked potentials from the hands and feet were within normal limits. Plasmapheresis (3 procedures, each 2 liter, with intravenous administration of 1 g of solu-medrol after each session) was performed in the acute phase, which benefited the decrease in severity of the neurological symptoms. Vascular and metabolic therapy was performed afterwards, with the regression of the neurologic symptoms. No specific therapy was administered after the woman was discharged from the hospital. For a 10-year survey after the acute demyelinating process outbreak there’s a complete regression of neurologic symptoms and positive dynamics of the patient’s MRI. The woman is fully adapted physically, emotionally and socially.
ICD-11 Beta Draft (Mortality and Morbidity Statistics) URL: http://apps. who.int/classifications/icd11/browse/l-m/en.
Instructions for medical use of the drug Levamisole. URL: http://www.rlsnet. ru/mnn_index_id_692.htm. (In Russ.)
Wu V.C., Huang J.W., Lien H.C. et al. Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. Medicine (Baltimore) 2006; 85: 203–213. DOI: 10.1097/01.md.0000230250.95281.60. PMID: 16862045.
Yan R., Wu Q., Ren J. et al. Clinical features and magnetic resonance image analysis of 15 cases of demyelinating leukoencephalopathy induced by levamisole. Exp Ther Med 2013; 6: 71–74. DOI: 10.3892/etm.2013.1077. PMID: 23935721.
Xu N., Zhou W., Li S. et al. Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patients. J Neuroimaging 2009; 19: 326–331. DOI: 10.1111/j.1552-6569.2008.00344.x. PMID: 19187474.
Gilbert J.W. Comment on Xu N., Zhou W., Shuy L. et al. Clinical and MRI characteristics of Levamisole-induced leukoencephalopathy in 16 patients1. J Neuroimaging 2011; 21: e188. DOI: 10.1111/j.1552-6569.2010.00466.x. PMID: 20136695.
Kimmel D.W., Wijdicks E.F.M., Rodriguez M. Multifocal inflammatory leukoencephalopathy associated with levamisole therapy. Neurology 1995; 45: 374–376. http://dx.doi.org/10.1212/wnl.45.2.374. PMID: 7854541.
Savarese D.M., Gordon J., Smith T.W. et al. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole: The use of thallium SPECT imaging to assist in noninvasive diagnosis. A case report. Cancer 1996; 77: 387–394. DOI: 10.1002/(sici)1097-0142(19960115)77:2<387::aidcncr23& gt;3.0.co;2-x. PMID: 8625249.
Israel Z.H., Lossos A., Barak V. et al. Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole. Acta Oncologica 2000; 39: 117–120. DOI: 10.1080/028418600431085. PMID: 10752665.
Wang C.H., Jeng J.S., Yip P.K. Multifocal leukoencephalopathy induced by levamisole: a case report. Acta Neurol Taiwan 2002; 11: 205–208.
Sariaslani P., Ghanbari A., Ghanbari P. Multifocal inflammatory leukoencephalopathy induced by accidental consumption of levamisole: A case report.Iran J Neurol 2012; 11: 65–69. PMID: 24250864.
Liu H.M., Hsieh W.J., Yang C.C. et al. Leukoencephalopathy induced by levamisole alone for the treatment of recurrent aphthous ulcers. Neurology 2006; 67: 1065–1067. DOI: 10.1212/01.wnl.0000237344.06122.79. PMID: 17000980.
Franco D.A., Greenberg H.S. 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency. Neurology 2001; 56: 110–112. PMID: 11148247.
Chang H.P., Kuo H.C., Yen T.C., Huang C.C. Multifocal demyelinating leukoencephalopathy induced by Levamisole therapy. Chang Gung Med J 2006; 29(Suppl): 90–96.
Cheng Y.C., Po H.L. Leukoencephalopathy after levamisole for the treatment of verrucae. Acta Neurol Taiwan 2011; 20: 262–266. PMID: 22315177.
Miskin D.P., Ngo L.H., Koralnik I.J. Diagnostic delay in progressive multifocal leukoencephalopathy. Ann Clin Transl Neurol 2016; 3: 386–391. DOI:10.1002/acn3.301. PMID: 27231708.
Shmidt T.E. [Progressive multifocal leukoencephalopathy and other neurological symptoms of active JC virus]. Neurological journal 2014; 4(19): 4–10. (In Russ.)
Long L., Song Y., Xu L., Xiao B. Levamisole-induced leukoencephalopathy mimicking Baló disease. Neurology 2015; 84: 328. DOI: 10.1212/ WNL.0000000000001150. PMID: 25601882.
Melnikov M.V., Boiko O.V., Lashch N.Yu. et al. [Acute disseminated encephalomyelitis and multiple sclerosis: open questions of differential diagnosis demonstrated by the example of a clinical case]. Zh Nevrol Psikhiatr Im S S Korsakova 2012; 112(9–2): 52–58. (In Russ.). PMID: 23235425.
Makarov N.S. [Differential diagnosis of multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system]. Nevrologicheskiy zhurnal 2015; 20(6): 4–9. DOI: 10.18821/1560-9545-2015-20-6-4-9. (In Russ.)
Yakhno N.N., Shmidt T.E., Damulin I.V. et al. [Multiphase acute disseminated encephalomyelitis]. Nevrologicheskiy zhurnal 2010; 15(6): 40–46. (In Russ.)